期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Dehydroepiandrosterone sulfate supplementation in health and diseases
1
作者 parth jethwani Ashu Rastogi Ravindra Shukla 《World Journal of Meta-Analysis》 2023年第4期102-111,共10页
Dehydroepiandrosterone sulfate(DHEAS)is a hormone produced by the zona reticularis of the adrenal gland and the ovaries.Initially considered as an inert compound merely serving as an intermediate in the conversion of ... Dehydroepiandrosterone sulfate(DHEAS)is a hormone produced by the zona reticularis of the adrenal gland and the ovaries.Initially considered as an inert compound merely serving as an intermediate in the conversion of cholesterol to androgens,interest in DHEA began to grow in the 1960s when it was found that DHEAS is the most abundant steroid hormone in human plasma and that its levels decline with age.In many countries,DHEA is considered a nutritional supplement.It has been used for a multitude of conditions which include sexual dysfunction,infertility,genitourinary syndrome of menopause,musculoskeletal disorders,cardiovascular diseases,ageing,neurological diseases,autoimmune conditions,adrenal insufficiency,and anorexia nervosa.We describe an overview of the historical evolution of DHEA,its physiology,and the disease states where it has been evaluated as a supplement. 展开更多
关键词 DEHYDROEPIANDROSTERONE ADRENAL Health supplements HYPOTHYROIDISM AUTOIMMUNITY DEPRESSION Cardiovascular disease
下载PDF
Non-medicalization of medical science:Rationalization for future
2
作者 Madhukar Mittal parth jethwani +1 位作者 Dukhabandhu Naik MK Garg 《World Journal of Methodology》 2022年第5期402-413,共12页
As we delve into the intricacies of human disease,millions of people continue to be diagnosed as having what are labelled as pre-conditions or sub-clinical entities and may receive treatments designed to prevent furth... As we delve into the intricacies of human disease,millions of people continue to be diagnosed as having what are labelled as pre-conditions or sub-clinical entities and may receive treatments designed to prevent further progression to clinical disease,but with debatable impact and consequences.Endocrinology is no different,with almost every organ system and associated diseases having subclinical entities.Although the expansion of these“grey”pre-conditions and their treatments come with a better understanding of pathophysiologic processes,they also entail financial costs and drug adverse-effects,and lack true prevention,thus refuting the very foundation of Medicine laid by Hippocrates“Primum non nocere”(Latin),i.e.,do no harm.Subclinical hypothyroidism,prediabetes,osteopenia,and minimal autonomous cortisol excess are some of the endocrine preclinical conditions which do not require active pharmacological management in the vast majority.In fact,progression to clinical disease is seen in only a small minority with reversal to normality in most.Giving drugs also does not lead to true prevention by changing the course of future disease.The goal of the medical fraternity thus as a whole should be to bring this large chunk of humanity out of the hospitals towards leading a healthy lifestyle and away from the label of a medical disease condition. 展开更多
关键词 PREDIABETES Subclinical hypothyroidism OSTEOPENIA Mild autonomous cortisol secretion PRE-CLINICAL MEDICALIZATION
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部